MEREO BIOPHARMA GROUP PLC Increase (Decrease) in Accounts Payable
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase (Decrease) in Accounts Payable of -$180.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$2.14M.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.96M, a 440.61% increase year-over-year.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $447.00K, a 46.98% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$236.00K.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accounts payable for fiscal 2025 was -$1.38M, a 1043.84% decline from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accounts payable for fiscal 2024 was $146.00K.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accounts payable for fiscal 2023 was -$1.26M, a 304.70% decline from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in accounts payable for fiscal 2022 was $617.00K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$180.00K 10-Q · filed 2026-08-11 | $267.00K derived: sum of 3 quarters · filed 2026-08-11 | $31.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.96M 10-Q · filed 2026-05-12 | $2.40M derived: sum of 2 quarters · filed 2026-05-12 | $2.17M derived: sum of 3 quarters · filed 2026-05-12 | $217.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $447.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $211.00K derived: sum of 2 quarters · filed 2026-03-19 | -$1.74M derived: sum of 3 quarters · filed 2026-08-11 | -$1.38M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$236.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$2.19M derived: sum of 2 quarters · filed 2026-08-11 | -$1.82M 10-Q · filed 2025-11-10 | -$982.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$1.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$1.59M 10-Q · filed 2026-08-11 | -$746.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.81M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $362.00K 10-Q · filed 2026-05-12 | $1.21M derived: sum of 2 quarters · filed 2026-05-12 | $140.00K derived: sum of 3 quarters · filed 2026-05-12 | $381.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $843.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$222.00K derived: sum of 2 quarters · filed 2026-03-19 | $19.00K derived: sum of 3 quarters · filed 2026-03-19 | $146.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$824.00K derived: sum of 2 quarters · filed 2025-11-10 | -$697.00K 10-Q · filed 2025-11-10 | $290.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $241.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $368.00K 10-Q · filed 2025-08-12 | $1.35M derived: sum of 3 quarters · filed 2025-08-12 | $599.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $127.00K 10-Q · filed 2025-05-13 | $1.11M derived: sum of 2 quarters · filed 2025-05-13 | $358.00K derived: sum of 3 quarters · filed 2025-05-13 | -$1.95M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $987.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $231.00K derived: sum of 2 quarters · filed 2025-03-26 | -$2.08M derived: sum of 3 quarters · filed 2025-03-26 | -$1.26M 10-K · filed 2025-03-26 |
| 2023-09-30 | -$756.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.06M derived: sum of 2 quarters · filed 2024-11-12 | -$2.25M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.49M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $812.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $617.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |